-
What is the reason why distributors such as Sinopharm, China Resources and Shanghai Pharmaceuticals are so good in hospitals?
Time of Update: 2021-11-15
Therefore, data shows that only giant companies such as Sinopharm, Shanghai Pharmaceuticals, China Resources Pharmaceuticals, and Jointown are eligible to be listed on the candidate list of medical consumables distributors for large hospitals .
-
Junshi Biological Appoints Vice President of Medical Sciences, worked in FDA for nearly 20 years
Time of Update: 2021-11-15
Maher worked in the US Food and Drug Administration (FDA) for nearly 20 years, serving as a clinical reviewer of the Office of Oncology Products, and a clinical review team of the Office of Cell, Tissue and Gene Therapy of the Center for Biologics Evaluation and Research (CBER) Chief, the clinical review team leader of the Blood and Tumor Products Office of the Center for Drug Evaluation and Research (CDER) .
-
Teriplizumab is expected to be approved in the U.S. in April next year
Time of Update: 2021-11-15
On October 31, Junshi Biotech announced that the FDA has accepted and granted priority review for the Biological Products License (BLA) for two nasopharyngeal cancer indications for teriprizumab.
-
Shuyu civilians: 413 stores added in 9 months
Time of Update: 2021-11-15
In the first three quarters of this year, Shuyu Civilian expanded to 413 new stores, and the number of new stores in the same period last year was 93, a year-on-year increase of 344.
-
As China vigorously promotes the development of pharmaceutical innovation, multinational pharmaceutical companies are accelerating reforms
Time of Update: 2021-11-15
Based on the above, the industry believes that behind the drastic reforms of multinational pharmaceutical companies, in addition to being affected by the implementation of China's pharmaceutical industry policies in recent years, more importantly, the trend of the Chinese market environment is gradually shifting from generic drugs to innovation .
-
Novartis's first complement factor B inhibitor iptacopan has been certified by the British Innovation Passport
Time of Update: 2021-11-15
Novartis recently announced that the British Medicines and Healthcare Products Regulatory Agency (MHRA), the National Institute of Health and Clinical Optimization (NICE), and the Scottish Medical Federation (SMC) have awarded oral therapy iptacopan (LNP023) for the treatment of C3 glomeruli "Innovation Passport" qualification for disease (C3G) .
-
From November 1st, many traditional Chinese medicine products have been included in the scope of medical insurance payment
Time of Update: 2021-11-15
As Chinese medicine formula granules and Chinese medicine decoction pieces have been included in the scope of national and even local medical insurance reimbursements, the industry believes that it will have a huge impact on the Chinese medicine market .
-
280 pharmacies have a good harvest
Time of Update: 2021-11-15
25 million yuan, involving 12 stores, and the equity transfer procedures of the project were completed in July 2021 .
79 million yuan, involving 20 stores, the project equity delivery procedures were completed in August .
-
Dongyang Sun Pharmaceutical "Insulin Glargine" Approved for Listing
Time of Update: 2021-11-15
cn/v5/home/)In the sixth round of centralized insulin procurement of the list announced in September, the products included are all second- and third-generation insulins, grouped by quick-acting, basic and premix .
-
ADC vs PDC——Inventory of current status of ADC-PDC drug research and development at home and abroad
Time of Update: 2021-11-15
The FDA accelerated the approval of Pepaxto combined with dexamethasone for the treatment of patients with relapsed refractory multiple myeloma (RRMM), based on the results of a pivotal phase II clinical trial (HORIZON), these patients have previously received at least four previous therapies, including proteases Body inhibitors, immunomodulators, monoclonal antibodies targeting CD38 .
-
Tianyan Pharmaceuticals launches a clinical trial cooperation of ADG106 combined with nivolumab in the treatment of patients with non-small cell lung cancer in Singapore
Time of Update: 2021-11-15
The Phase Ib/II trial will evaluate the efficacy of this new combination therapy in advanced non-small cell lung cancer (NSCLC) patients who have progressed after previous treatment .
-
Major pharmaceutical companies have expanded their production capacity, and the demand for pharmaceutical equipment may continue to increase
Time of Update: 2021-11-15
For example, in order to help pharmaceutical companies improve production efficiency and further ensure drug quality, many companies have developed numerous intelligent and fully automatic equipment and production lines, which have also been widely used in the pharmaceutical production process .
-
On the evening of October 26, it was announced that a number of pharmaceutical companies disclosed their three quarterly reports, and one company released an annual performance forecast
Time of Update: 2021-11-15
62%; non-recurring gains and losses attributable to shareholders of listed companies were deducted The net profit of 905 million yuan, a year-on-year increase of 19.
On the same day, the third quarter report disclosed by Liuyao shares showed that the company achieved operating income of 12.
-
This kind of Chinese medicine companies paid attention to the new national policy on November 1st!
Time of Update: 2021-11-15
According to the requirements of the "Notice", from November 1, 2021, The Chinese medicine formula granule varieties are subject to record management, and they need to be filed with the State Food and Drug Administration to obtain a record number before they are put on the market .
-
Mixed joys and sorrows!
Time of Update: 2021-11-15
The total MADRS score of the patients who received 3 mg/day showed improvement in the 6th week, but it did not reach statistical significance compared with the control group .
-
The world's first basal insulin GLP-1RA injection Novo is approved in China
Time of Update: 2021-11-15
Novoyi® is the world's first basal insulin glucagon-like peptide-1 receptor agonist (GLP-1RA) injection, which is composed of insulin deglubber and liraglutide [2], a breakthrough integration of deglu The two-component advantages of insulin and liraglutide, complementary mechanisms, multi-targeted action on multiple pathophysiological mechanisms of type 2 diabetes[3],[4],[5], once a day, powerful control of blood sugar throughout the day , The glycated hemoglobin (HbA1c) compliance rate is as high as 89.
-
Recently, the price of Chinese medicinal materials has generally risen. How will it affect related listed companies?
Time of Update: 2021-11-15
Regarding the increase in the price of raw materials, Tasly responded that the company has its own GAP planting base, and Panax notoginseng also has a strategic reserve of medicinal resources, which can reduce the impact of medicinal material price fluctuations on cost procurement .
-
Announcement of the State Food and Drug Administration on Revising the Instructions for Propylthiouracil Preparations (No. 103 of 2021)
Time of Update: 2021-11-14
The marketing authorization holders of the above-mentioned drugs shall be in accordance with the "Administrative Measures for Drug Registration" and other relevant regulations, and in accordance with the requirements for the revision of the propylthiouracil preparation instructions (see attachment), before November 22, 2021 Report to the provincial drug supervision and administration department for the record .
-
Pharmaceutical companies showed strong willingness to invest in R&D, allowing R&D to be in the “C” position
Time of Update: 2021-11-14
Data shows that in the first three quarters of this year, some listed pharmaceutical companies invested more than 100 million yuan in research and development, and their share of revenue continued to increase .
In recent years, China's pharmaceutical companies have continuously increased their R&D investment.
-
Approval of Sintilimab's new indication application for frustrated potential is still optimistic
Time of Update: 2021-11-14
However, due to unpredictable circumstances, Sintilimab received a drug notification for the first time in China, and the listing application for a single-drug second-line treatment of squamous non-small cell lung cancer was not approved .
